MARKET NEWS

Xynomic Pharma Reports Encouraging Interim Data From Phase 1b Study
Big pharma Secures Orphan Drug Designations Through M&As
Esperion Announces Positive Top-Line Results From Phase 2 Study
Kintai Therapeutics Announces Collaborations With Leading Academic Centers
PCI Pharma Services Announces Agreement to Acquire Sherpa Clinical Packaging
Adaptimmune & Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products

  FEATURED EDITORIAL

  COMPANY PROFILE

 

Frontida BioPharm, Inc. is a leading provider of  product development and manufacturing services for both small and large biotech, pharmaceutical, and consumer health companies. Combining the rich heritage of resources from URL/Mutual Pharmaceuticals in Philadelphia, PA, and Aurora, IL, with the development expertise from Frontage Laboratories and the region’s best pharmaceutical companies, Frontida is helping our partners reach the market faster, ensuring robust product performance and on-time supply of clinical and commercial products. Our 300,000-sq-ft manufacturing facilities supply prescription and OTC products, Highly Potent Active Ingredient (HPAI) products, Fixed-dose Combination Products, and DEA schedules II–V products. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Hovione Signs Collaboration Agreement With Kiel University on High-Dose Dry Powder Inhalation Delivery

Hovione Signs Collaboration Agreement With Kiel University on High-Dose Dry Powder Inhalation Delivery

Hovione Technology recently announced it has entered into a collaboration agreement with Kiel University, Institute of Pharmacy in Germany, a reference research institution on inhaled drug delivery.

Gerresheimer Expands the Gx RTF ClearJect Product Line

Gerresheimer Expands the Gx RTF ClearJect Product Line

Gerresheimer recently announced it is expanding its range of prefillable polymer syringes to include a new product: the Gx RTF ClearJect polymer needle syringe, 2.25 ml. Like the 1.0 ml syringe, this syringe will be……..

Ajinomoto Bio-Pharma Services Acquires Remaining Interest in Granules OmniChem Joint Venture in India

Ajinomoto Bio-Pharma Services Acquires Remaining Interest in Granules OmniChem Joint Venture in India

Ajinomoto Bio-Pharma Services recently announced its intention to purchase the remaining 50%  ownership interest in its Visakhapatnam, India, joint venture, Granules OmniChem Private Limited (GOC) from its….

Co-Processed Excipient for Direct Compression Designed for Orally Disintegrating Tablets

Co-Processed Excipient for Direct Compression Designed for Orally Disintegrating Tablets

Developing ODTs is a worldwide trend. In recent years, new excipients and excipient blends have enabled manufacturers to produce ODTs using conventional equipment, ie, blenders and tablet presses. One such product is GRANFILLER-D………

Creating Your Secondary Packaging Strategy - Begin With the End in Mind

Creating Your Secondary Packaging Strategy - Begin With the End in Mind

Whether it is meeting the needs of a rapidly aging market, blocking drug counterfeiters, or differentiating your pharmaceutical product in the market, a secondary packaging program is an important factor in………

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 11 – Injection Devices
September 18 – Lyophilization Manufacturing